- Ticker
- ADIL
- Price
- 0.57
- Stock movement up
- +0.02 (2.89%)
- Company name
- Adial Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 14.62M
- Ent value
- 5.19M
- Price/Sales
- -
- Price/Book
- 1.37
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -83.48%
- 3 year return
- -28.81%
- 5 year return
- -
- 10 year return
- -
Last updated: 2022-08-25
DIVIDENDS
ADIL does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.37 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 25.65M |
| EPS (TTM) | -0.88 |
| FCF per share (TTM) | -0.59 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -17.51M |
| Net income (TTM) | -17.50M |
| EPS (TTM) | -0.88 |
| EPS (1y forward) | -0.59 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 12.69M |
| Net receivables | 0.00 |
| Total current assets | 12.96M |
| Goodwill | 248.97K |
| Intangible assets | 4.90K |
| Property, plant and equipment | 0.00 |
| Total assets | 13.96M |
| Accounts payable | 415.09K |
| Short/Current long term debt | 51.35K |
| Total current liabilities | 2.17M |
| Total liabilities | 3.26M |
| Shareholder's equity | 10.71M |
| Net tangible assets | 10.00M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -11.60M |
| Capital expenditures (TTM) | 98.33K |
| Free cash flow (TTM) | -11.70M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -163.42% |
| Return on Assets | -125.31% |
| Return on Invested Capital | -162.64% |
| Cash Return on Invested Capital | -108.76% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.54 |
| Daily high | 0.59 |
| Daily low | 0.54 |
| Daily Volume | 142K |
| All-time high | 8.33 |
| 1y analyst estimate | 8.67 |
| Beta | 0.74 |
| EPS (TTM) | -0.88 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ADIL | S&P500 | |
| Current price drop from All-time high | -93.16% | -13.41% |
| Highest price drop | -93.35% | -56.47% |
| Date of highest drop | 23 Aug 2022 | 9 Mar 2009 |
| Avg drop from high | -69.04% | -11.38% |
| Avg time to new high | 93 days | 12 days |
| Max time to new high | 910 days | 1805 days |
COMPANY DETAILS
Marketcap
14.62M
Marketcap category
Small-cap
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Employees
16
Website
Investor relations
-
SEC filings
CEO
William B. Stilley
Country
USA
City
Charlottesville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of t...
26. september 2022
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 - Chronic Constrictive Injury Model (Rat) PNV-5030 - Chronic Constrictive Injury Model (Rat) CHARLOTTESVILLE, Va...
26. september 2022
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary Purnovate Inc achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory ...
6. september 2022
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model PNV-6005 - DSS-induced Ulcerative Colitis Model (Mice) PNV-6005 - DSS-induced Ulcerative Colitis Mod...
6. september 2022
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisi...
1. september 2022
Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises are part of Zacks Screen of the Week article.
29. august 2022
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enter...
26. august 2022
Kevin Schuyler appointed Chairman of Adial’s Board William Stilley moves to post of CEO of Adial’s subsidiary, Purnovate Company to host conference call at 8:30 a.m. EDT tomorrow CHARLOTTESVILLE, Va.,...
22. august 2022
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both European and U.S. regulatory agencies Act...
16. august 2022
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinki...
20. juli 2022
Next page